睿知中国医院研究地图
候选清单

正在招募淋巴瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06696846,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Relapsed/refractory T cell lymphoma is defined as: relapsed/refractory after having received at least two or more lines of previous treatment (patients with anaplastic large -cell lymphoma must have been exposed and resistant to Brentuximab vedotin). The celluar subtypes of T-cell lymphoma include: angioimmunoblastic T-cell lymphoma; peripheral T - cell lymphoma not otherwise specified; ALK-negative anaplastic large - cell lymphoma; Relapsed/refractory AML is defined as: leukemia cells reappear in the peripheral blood after complete remission or the blasts in the bone marrow ≥ 5% or the extramedullary leukemia infiltration outside. Or newly diagnosed cases did not achieve a CR after two courses of standard regimens; those who relapse within 12 months after CR after consolidation and intensification treatment; those who relapse after 12 months and have not responded to conventional chemotherapy; those who relapse two or more times; those with persistent extramedullary leukemia;

    入选标准第 3 条

    Patients who have previously received CAR - T cell therapy and were evaluated as ineffective after 3 months or relapsed after CR are allowed;

    入选标准第 16 条

    Those who have received gene therapy within the past 3 months;

    排除标准第 4 条

    Those whose toxic reactions from previous anti - tumor treatment have not recovered (CTCAE 5.0 toxic reactions have not recovered to ≤ grade 1, except for fatigue, anorexia, and alopecia);

    排除标准第 8 条

  3. ECOG score is 0 - 2;

    入选标准第 6 条

  4. Creatinine clearance rate (Cockcroft - Gault method) ≥ 60 mL/min;

    入选标准第 9 条

    Serum total bilirubin and alkaline phosphatase ≤ 1.5× UNL;

    入选标准第 10 条

    Routine blood test: absolute neutrophil count > 1000/mm3, platelet count ≥ 45×109, hemoglobin ≥ 8.0g/dl (the standard for AML patients is ≥ 7.0g/dl; blood transfusion is allowed);

    入选标准第 14 条

  5. Subjects with hepatitis B (HBsAg - positive, but HBV - DNA < 103 is not an exclusion criterion) or hepatitis C virus infection (including virus carriers), syphilis, and other acquired or congenital immunodeficiency diseases, including but not limited to those infected with the AIDS virus;

    排除标准第 6 条

  6. Female subjects of childbearing age must have a negative pregnancy test and agree to take effective contraceptive measures during the trial period;

    入选标准第 17 条

    Lactating women who are unwilling to stop breastfeeding;

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06696846,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily participate in this study and sign the informed consent form;
  2. Aged between 18-75 years old, both male and female are eligible;
  3. Relapsed/refractory T cell lymphoma is defined as: relapsed/refractory after having received at least two or more lines of previous treatment (patients with anaplastic large -cell lymphoma must have been exposed and resistant to Brentuximab vedotin). The celluar subtypes of T-cell lymphoma include: angioimmunoblastic T-cell lymphoma; peripheral T - cell lymphoma not otherwise specified; ALK-negative anaplastic large - cell lymphoma; Relapsed/refractory AML is defined as: leukemia cells reappear in the peripheral blood after complete remission or the blasts in the bone marrow ≥ 5% or the extramedullary leukemia infiltration outside. Or newly diagnosed cases did not achieve a CR after two courses of standard regimens; those who relapse within 12 months after CR after consolidation and intensification treatment; those who relapse after 12 months and have not responded to conventional chemotherapy; those who relapse two or more times; those with persistent extramedullary leukemia;
  4. The expected survival period ≥ 12 weeks;
  5. CD70 expression is positive in tumor tissue puncture sections/tumor cells detected by flow cytometry, and the number of CD70 - positive cells detected by immunohistochemistry ≥ 20% (++ or more);
  6. ECOG score is 0 - 2;
  7. Adequate organ function reserve:
  8. Alanine aminotransferase and aspartate aminotransferase ≤ 2.5× UNL;
  9. Creatinine clearance rate (Cockcroft - Gault method) ≥ 60 mL/min;
  10. Serum total bilirubin and alkaline phosphatase ≤ 1.5× UNL;
  11. Glomerular filtration rate > 50 ml/min;
  12. Cardiac ejection fraction ≥ 45%;
  13. Under indoor natural air environment, the basic oxygen saturation > 92%;
  14. Routine blood test: absolute neutrophil count > 1000/mm3, platelet count ≥ 45×109, hemoglobin ≥ 8.0g/dl (the standard for AML patients is ≥ 7.0g/dl; blood transfusion is allowed);
  15. Previous autologous hematopoietic stem cell transplantation is allowed once;
  16. Patients who have previously received CAR - T cell therapy and were evaluated as ineffective after 3 months or relapsed after CR are allowed;
  17. Female subjects of childbearing age must have a negative pregnancy test and agree to take effective contraceptive measures during the trial period;
  18. No active lung infection, and indoor air blood oxygen saturation ≥ 92%;
  19. Before the study drug is used, approved anti - tumor treatment methods, such as systemic chemotherapy, whole - body radiotherapy, and immunotherapy, have been completed for at least 3 weeks; the wash - out period for targeted drug regimens without chemotherapy is 2 weeks;
  20. Two negative tests for COVID - 19 or influenza A.

排除标准:Exclusion Criteria:

  1. Those with a history of allergy to any component in the cellular product;
  2. Those with a history of other tumors;
  3. Those who had grade II - IV (Glucksberg criteria) acute GvHD or extensive chronic GvHD after previous allogeneic hematopoietic stem cell transplantation; or those who are currently receiving anti - GvHD treatment;
  4. Those who have received gene therapy within the past 3 months;
  5. Those with active infections requiring treatment (except for simple urinary tract infections and bacterial pharyngitis). However, prophylactic antibiotic, antiviral, and antifungal treatments are permitted;
  6. Subjects with hepatitis B (HBsAg - positive, but HBV - DNA < 103 is not an exclusion criterion) or hepatitis C virus infection (including virus carriers), syphilis, and other acquired or congenital immunodeficiency diseases, including but not limited to those infected with the AIDS virus;
  7. Subjects with grade III or IV cardiac insufficiency according to the New York Heart Association cardiac function classification standard of the United States;
  8. Those whose toxic reactions from previous anti - tumor treatment have not recovered (CTCAE 5.0 toxic reactions have not recovered to ≤ grade 1, except for fatigue, anorexia, and alopecia);
  9. Subjects with a history of epilepsy or other central nervous system diseases;
  10. Lactating women who are unwilling to stop breastfeeding;
  11. Any other circumstances that, in the opinion of the investigator, may increase the risk to the subject or interfere with the test results;
  12. Those with positive nucleic acid tests for COVID - 19 or influenza A.

引自 ClinicalTrials.gov, NCT06696846, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06696846,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06696846